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Background. It is unclear whether hepatitis B e antigen (HBeAg) seroconversion induced by nucleos(t)ide analogues (NUC) has a prognosis that is similar to that of spontaneous HBeAg seroconversion.
Methods. A total of 148 noncirrhotic NUC-induced HBeAg seroconverters were consecutively enrolled. A historical control of 407 noncirrhotic spontaneous HBeAg seroconverters was also recruited. We compared the rates of HBeAg seroreversion and HBV reactivation between these 2 cohorts.
Results. There were 1652.8 and 465.2 person-years of follow-up for spontaneous and NUC-induced HBeAg seroconverters, respectively. Compared with NUC-induced seroconverters, spontaneous seroconverters were younger when achieving HBeAg seroconversion. We thus compared these 2 cohorts according to their age at HBeAg seroconversion. In patients achieving HBeAg seroconversion before 30 years of age, NUC-induced seroconverters had a higher 2-year HBeAg seroreversion rate than spontaneous seroconverters (12.0% vs 2.9%; P = .004) and were at a higher risk of HBV reactivation (hazard ratio, 4.6; 95% confidence interval, 1.5-14.4). Using multivariate analysis, NUC-induced HBeAg seroconversion remained a risk factor of both endpoints in young HBeAg seroconverters.
Conclusion. NUC-induced HBeAg seroconverters may not have durable response after stopping therapy. For patients achieving HBeAg seroconversion before 30 years of age, the risk of HBeAg seroreversion and HBV reactivation is higher in NUC-induced seroconverters than spontaneous HBeAg seroconverters.
Hepatitis B virus (HBV) infection is a global health problem, resulting in more than 1 million deaths per year [1, 2] . Patients with chronic HBV infection have an increased risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC), with an estimated lifetime risk of 25%-40% [1] [2] [3] [4] .
Hepatitis B e antigen (HBeAg) seroconversion is known to be a milestone in the natural history of chronic HBV infection because it usually indicates a decline in viral replication and subsequent remission of liver disease [2, 5, 6] . Nevertheless, 20%-40% of spontaneous HBeAg seroconverters may have HBV reactivation after HBeAg seroconversion [6] [7] [8] [9] [10] . These patients are still at risk of developing cirrhosis and HCC over time.
Lamivudine, the first oral nucleos(t)ide analogue (NUC), has been shown to increase the chance of HBeAg seroconversion [11] [12] [13] . Thus, lamivudine and subsequent NUCs are recommended for treating HBeAg-positive patients who enter the immune clearance phase with alanine aminotransferase (ALT) elevation [14] [15] [16] . As a result of past therapeutic advances, many HBeAg seroconversions were induced by NUC treatment as oppose to spontaneous seroconversion. These measures may alter the natural history of HBV infection. Recent studies have indicated that NUC-induced HBeAg seroconversion may not be as durable as previously anticipated [17] [18] [19] . These data raise the question of whether the longterm prognosis of NUC-induced HBeAg seroconverters is as good as that for spontaneous HBeAg seroconverters.
A randomized controlled trial would be ideal for investigating this important issue; however, such a trial is almost impossible in the current era. Therefore, we compared NUCinduced HBeAg seroconverters with a historical control of spontaneous HBeAg seroconverters as an alternative method. We investigated the clinical differences between these 2 groups in terms of the risk of HBeAg seroreversion (HBeAg SR) and HBV reactivation. Figure 1A shows the flow of spontaneous HBeAg seroconverters enrolled in this study. Most patients were enrolled from the Study of E Antigen seRoClearance of Hepatitis B (SERACH-B) cohort [6, 20] . We made minor modifications to the enrollment criteria to match that of the NUC-induced cohort: we reintroduced patients who had HBeAg SR (N = 19) and those who had HBeAg-negative hepatitis within the first year after HBeAg seroconversion (N = 26). Both were not included in our prior studies. We excluded patients who had evidence of liver decompensation during the HBeAg-positive phase (N = 28) because they should be treated immediately. Therefore, the patient number increased from 390 to 407. Figure 1B shows the flow of NUC-induced HBeAg seroconverters enrolled into the study. From 2004 to 2009, 568 NUC-treated HBeAg-positive chronic hepatitis B patients were consecutively enrolled into this cohort. All of them were aged >18 years and positive for HBsAg for more than 6 months; none had evidence of concomitant hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus infection. All received NUC therapy at the National Taiwan University Hospital because their ALT levels were ≥2 times the upper limit of normal (ULN) [15, 16] . Among them, 191 (33.6%) patients experienced HBeAg seroconversion during NUC treatment. We excluded 21 patients who needed immediate and indefinite NUC therapy (5 with cirrhosis, 1 with HCC, and 15 with liver decompensation); 13 patients who did not meet the criteria to cease NUC therapy (8 with inadequate consolidation therapy and 5 with detectable HBV DNA levels at the end of therapy); and 9 patients who received irregular follow-up or had inadequate serum for analysis. A total of 148 NUC-induced HBeAg seroconverters were thus enrolled and stopped NUC therapy according to the treatment guidelines [14, 16] . All enrolled patients in both cohorts gave informed consent as approved by the National Taiwan University Hospital ethical committee.
MATERIALS AND METHODS

Patient Cohort
Data Collection
Before enrollment, patients were tested for serological markers (HBsAg, HBeAg, anti-HBe, antibodies against HCV [anti-HCV], and antibodies against HDV [anti-HDV]). For the treatment cohort, liver biochemical tests, HBeAg and antiHBe, were assayed at least every 3 months during treatment. After achieving HBeAg seroconversion in both groups, liver biochemical tests, HBeAg, and anti-HBe, were assayed every 3-6 months if ALT levels were within normal limits and at least every 1-3 months if ALT levels were elevated.
Definitions of HBeAg Seroconversion, HBeAg Seroreversion, HBeAg-Negative Hepatitis, and HBV Reactivation
Most of the definitions used in this study were described in our previous report [20] . For the spontaneous seroconverters, HBeAg seroconversion was defined as loss of HBeAg and detection of anti-HBe; for the NUC-induced seroconverters, HBeAg seroconversion was defined as loss of HBeAg and detection of anti-HBe that occurred during the treatment period and persisted until the end of therapy. HBeAg SR was defined as reappearance of HBeAg after HBeAg seroconversion. HBeAg-negative hepatitis was defined as elevation of ALT level to ≥2 times the ULN with concomitant serum HBV-DNA level ≥2000 IU/mL. The ULN of serum ALT level is 40 U/L. In addition, it was essential to exclude those patients with a history of drug or alcohol use and ensure the absence of serological evidence suggestive of other viral hepatitis infections or autoimmune liver disease.
We compared these 2 cohorts using 2 endpoints. The first endpoint was HBeAg SR. The second endpoint was HBV reactivation, defined as either emergence of HBeAg SR or HBeAgnegative hepatitis B, whichever came first.
Serological Assays
Serum HBsAg, HBeAg, anti-HBe, anti-HCV, and anti-HDV were tested using commercially available kits (Abbott Laboratories, Abbott Park, IL, USA).
Quantification of Serum HBV DNA level and HBV Genotyping
HBV viral load and genotype were determined using real-time polymerase chain reaction (PCR)-based single-tube assay as previously described [21] . Briefly, the method consists of 2 sequential steps. The first step uses real-time PCR to quantify HBV DNA level, and the second step uses melting curve analysis to determine HBV genotype. The dynamic range of HBV-DNA level under this method is from 20 to 2 × 10 10 IU/mL (100 to 10 11 copies/mL). For patients who had undetectable HBV DNA levels at the HBeAg-negative phase, we determined HBV genotype either by serotyping or using serum samples during the HBeAg-positive stage [22] .
Statistical Analysis
Means and SDs were calculated for continuous variables. Percentages were used for categorical variables. The calculation of person-years started from the time of HBeAg seroconversion for the spontaneous seroconverters but from the end of therapy for the NUC-induced seroconverters. As noted previously, we compared these 2 groups of patient using 2 endpoints: HBeAg SR and HBV reactivation. Because all HBeAg SR occurred within the first 2 years of follow-up in both groups, we analyzed this endpoint using the chi-square test or Fisher exact test when appropriate. Multivariableadjusted odds ratio (OR) and 95% confidence intervals (CIs) were derived for each factor using logistic regression.
Because HBV reactivation is a time-dependent variable, it was evaluated using the Kaplan-Meier method, and the statistical difference was derived using the log-rank test. The spontaneous seroconverters had a longer duration of followup because they were enrolled earlier than the NUC-induced seroconverters [6, 20] . To avoid the potential bias, we truncated the follow-up period of both groups at the end of the fifth year. The person-years were censored on the date of HBV reactivation, starting antiviral therapy, the last time of follow-up (30 June 2011), or the end of the fifth year, whichever came first. For patients with multiple episodes of HBV reactivation, the endpoint was only counted once in each patient. Multivariable-adjusted hazard ratios (HRs) and 95% CIs were derived for each factor using the Cox proportional hazards model.
Lines of evidence have shown that spontaneous HBeAg seroconverters with late seroconversion had worse outcomes than those with early seroconversion [6, 8, 23] . We thus categorized both cohorts using 3 age intervals of HBeAg seroconversion: 20-29 years, 30-39 years, and ≥40 years. The risk of each endpoint was compared between NUC-induced and spontaneous HBeAg seroconverters in the same age category. The results were adjusted by the shared risk factors, including sex and HBV genotype, using multivariate analysis.
All statistical tests were 2-tailed and P < .05 was considered as statistical difference. All analyses were performed using Stata statistical software (version 9.0; StataCorp, College Station, TX). 68.2%, P = .004) and were younger at the time of HBeAg seroconversion (mean age ± SD, 29.5 ± 9.3 vs 35.5 ± 10.0 years; P < .001). Most NUC-induced seroconverters received lamivudine treatment (92.6%) and the majority had a consolidation duration of 6-12 months (61.5%).
RESULTS
Baseline Characteristics
For spontaneous HBeAg seroconverters, the duration from the first episode of ALT level ≥2 times the ULN at the HBeAg-positive stage to HBeAg seroconversion (mean ± SD) was 27.6 ± 31.2 months. For NUC-induced HBeAg seroconverters, the duration from initiating treatment to HBeAg seroconversion was 9.0 ± 11.6 months, which was shorter than the duration for the spontaneous group to achieve HBeAg seroconversion (P < .001).
Risk Factors of HBV Reactivation in 148 NUC-Induced HBeAg Seroconverters
We first investigated the relationships between HBV reactivation and common risk factors, including age at HBeAg seroconversion, sex, HBV genotype, pretreatment HBV DNA and ALT levels, and consolidation duration, in 148 NUC-induced HBeAg seroconverters. The pretreatment HBV DNA level was categorized into <2 × 10 7 IU/mL and ≥2 × 10 7 IU/mL according to a prior report [24] . The results showed that, unlike spontaneous HBeAg seroconversion, age was not associated with HBV reactivation. The pretreatment HBV DNA level ≥2 × 10 7 IU/mL was the only risk factor of HBV reactivation with HR of 2.5 (95% CI, 1.5-4.2) using multivariate analysis ( Table 2) .
Comparison of 2-year HBeAg Seroreversion Rates Between Spontaneous and NUC-Induced HBeAg Seroconverters Categorized by Age at HBeAg Seroconversion
We compared spontaneous and NUC-induced HBeAg seroconverters in terms of HBeAg SR rate and adjusted the results with shared risk factors, including age at HBeAg seroconversion, sex, and HBV genotype. There were 24 and 22 episodes of HBeAg SR for spontaneous and NUC-induced seroconverters, respectively, and all of them occurred within the first 2 years of follow-up. The NUC-induced seroconverters had a higher rate of HBeAg SR than spontaneous seroconverters (14.9% vs 5.9%, P = .001) (Figure 2A ). When performing subgroup analysis in different age intervals, the difference only remained in patients who achieved HBeAg seroconversion before age 30 years (12.0% vs 2.9%, P = .004), but not in other age categories (Figure 2A ). Using multivariate analysis, NUCinduced HBeAg seroconversion (OR, 4.8; 95% CI, 1.4-15.5) and genotype C infection (OR, 7.2; 95% CI, 2.2-23.2) were 2 independent risk factors for patients achieving HBeAg seroconversion at age <30 years (Table 3) .
5-year Cumulative Incidence Rates of HBV Reactivation in Spontaneous and NUC-Induced Seroconverters Categorized by Different Age Intervals
There were 1652.8 and 465.2 person-years of follow-up with an average follow-up period of 4.1 and 3.1 years for spontaneous and NUC-induced seroconverters, respectively. Throughout this period, there were 103 episodes of HBV reactivation with an average annual incidence rate of 6.2% for spontaneous seroconverters and 77 episodes of HBV reactivation with an average annual incidence rate of 13.2% for NUC-induced seroconverters. In both groups, most of the HBV reactivations were censored by HBeAg-negative hepatitis (83.5% for spontaneous seroconverters and 81.8% for the NUC-induced seroconverters) ( Table 1) . Compared with spontaneous HBeAg seroconverters, NUCinduced HBeAg seroconverters had a higher risk of HBV reactivation either in the whole cohort or in each age-stratified subcohort ( Figure 2B-E) . Using univariate analysis, the HRs (95% CI) of HBV reactivation for NUC-induced HBeAg seroconversion were 5.4 (3.2-9.0) for age at HBeAg seroconversion <30 years, 1.8 (1.1-3.1) for age between 30 and 39 years, and 1.7 (1.0-2.8) for age ≥40 years (Table 4) . Using multivariate analysis, we found that NUC treatment remained a risk factor of HBV reactivation in patients with age at HBeAg seroconversion <30 years and 30-39 years with HRs of 4.7 (2.8-7.8) and 1.8 (1.0-3.0), respectively (Table 4) .
Cumulative Incidence Rates of Late HBV Reactivation in Spontaneous and NUC-Induced HBeAg Seroconverters Categorized by Different Age Intervals
From the Kaplan-Meier method (Figure of 2B) , we found that the risk of HBV reactivation increased rapidly after the withdrawal of NUC but slowed down and reached a stable rate 6 months after stopping treatment. Because early HBV reactivation is assumed to be related to insufficient suppression of virus, we thus investigated whether the difference between NUC-induced and spontaneous HBeAg seroconversion still exists in terms of late HBV reactivation. We enrolled patients whose person-years were not censored before 6 months of follow-up in both cohorts (N = 403 for the spontaneous group and N = 108 for the NUC group). The endpoint was late HBV reactivation, which was defined as HBV reactivation occurring after 6 months of follow-up. In the overall cohort, the risk was still higher in NUC-induced HBeAg seroconverters than in spontaneous ones ( Figure 3A ; HR, 1.7; 95% CI, 1.2-2.5; P = .006). The difference remained unchanged when patients achieving HBeAg seroconversion were < 30 years ( Figure 3B ; HR, 2.6; 95% CI, 1.3-5.1; P = .005) but not in patients achieving HBeAg seroconversion at age 30-39 years ( Figure 3C ; P = .750) and ≥40 years ( Figure 3D ,;P = .821). 
DISCUSSION
Current lines of evidence have indicated that HBV reactivation increases the risk of cirrhosis and HCC development in HBV carriers [7] [8] [9] [10] . Therefore, the treatment goal for HBeAg-positive patients should not only be an initial response of HBeAg seroconversion but also a durable response that is permanently free from HBV reactivation. Our study first showed that age at HBeAg seroconversion was not associated with HBV reactivation in NUC-induced HBeAg seroconverters. Because age affects the prognosis in spontaneous HBeAg seroconverters [6, 8, 23] , we wondered whether the prognosis difference between spontaneous and NUC-induced HBeAg seroconverters was age-specific. We found that in patients achieving HBeAg seroconversion <30 years of age, NUC-induced HBeAg seroconverters were at a higher risk of HBeAg SR and HBV reactivation than spontaneous HBeAg seroconverters. In contrast, the prognosis was comparable between NUC-induced and spontaneous HBeAg seroconverters who experienced HBeAg seroconversion after 40 years of age. International treatment guidelines have recommended that HBeAg-positive patients initiate antiviral therapy once they have entered the immune clearance phase [14] [15] [16] . This is because a prolonged immune clearance phase is associated with more liver damage and a higher risk of cirrhosis and HCC [25] , also NUC therapy increases the chance of HBeAg seroconversion [14] [15] [16] , thus shortening the immune clearance phase. However, little is known about the long-term benefit of this strategy, such as decreasing incidence of HBV reactivation [2] . In this study, we found that young (<30 years) NUC-induced HBeAg seroconverters, when compared with spontaneous seroconverters, had a higher risk of HBV reactivation. Because a longer or even indefinite treatment is indicated for patients with HBeAg-negative hepatitis, these data may raise the concern that treating young HBeAg-positive patients with NUC predisposes them to HBV reactivation after HBeAg seroconversion and places them in a situation that is difficult to manage. In addition, these young HBeAgpositive patients are usually at the early stages of the immune clearance phase and may have the likelihood of spontaneous HBeAg seroconversion. Taking these facts and our findings together, 3-6 months of close observation may be more appropriate than immediate NUC therapy in young and nondecompensated HBeAg-positive chronic hepatitis B patients. This measure may ensure the chances of spontaneous HBeAg seroconversion. More importantly, we should search for factors predicting whether spontaneous HBeAg seroconversion will occur within 3-6 months after an episode of hepatitis. With these predictors, it would be possible to predict which patients will convert HBeAg spontaneously and then decide whether waiting or initiating treatment immediately is a better policy. It is still unclear why different mechanisms of HBeAg seroconversion lead to different prognosis. One explanation is that different processes of HBeAg seroconversion may result in various levels of viral suppression. For example, prior studies have indicated that HBV DNA levels gradually decline during the course of spontaneous HBeAg seroconversion [6, 20, 26] . In contrast, HBV DNA levels may increase abruptly after stopping NUC therapy [17, 19] . If viral replication can serve as a potential indicator for immune control, these facts may help explain why NUC-induced HBeAg seroconverters have a worse prognosis than spontaneous ones.
Several unique features existed in our study. First, we investigated the possible risk factors of HBV reactivation in NUC-induced HBeAg seroconverters and found that a higher pretreatment HBV DNA level was the only risk factor. This finding was consistent with a prior report, which validated the data accuracy of an NUC-induced HBeAg seroconversion cohort [24] . Second, all of the enrolled NUC-induced HBeAg seroconverters received a minimum of 6 months of consolidation therapy and their HBV DNA levels were <20 IU/mL at the end of therapy [16] . We excluded patients who had cirrhosis, HCC, and liver decompensation during the HBeAg-positive phase in both groups because these patients should receive immediate and indefinite therapy [14] [15] [16] . In other words, all of our NUC-induced HBeAg seroconverters received the current standard of care and the data generated from this cohort could represent the real-world situation. Third, when analyzing the data, we found that there were 2 patterns of HBV reactivation in NUC-induced HBeAg seroconverters. The first pattern was early HBV reactivation, which occurred within the 6 months of follow-up and increased rapidly. The second pattern was late HBV reactivation, which occurred after the 6 months of followup and increased slowly. We speculated that early HBV reactivation may be caused by suboptimal viral suppression due to the less potent drug or inadequate duration of consolidation therapy. To have a fair comparison between these 2 cohorts, we used late HBV reactivation as another endpoint and consistently found that young NUC-induced HBeAg seroconverters were at a higher risk of late HBV reactivation.
Using historical control is more likely to introduce selection bias than a randomized controlled study. In our results, age at HBeAg seroconversion makes quite a difference between these 2 cohorts, and this factor has been shown to affect the prognosis in spontaneous HBeAg seroconverters [6, 8, 23] . To address this issue, we categorized the patients by different ranges of age at HBeAg seroconversion and compared their prognosis in each strata. Using stratification helped us resolve this issue. Another possible bias comes from the different approaches for managing HBeAg-positive patients: patients with more severe hepatitis were likely to receive NUC therapy, while those with milder disease might receive observation only. Because a higher hepatitis activity in the immune clearance phase has been shown to be associated with worse outcomes after HBeAg seroconversion [8] , this might introduce another selection bias if we enroll spontaneous and NUCinduced HBeAg seroconverters in the same period. To minimize this bias, which is introduced by different management approaches, we made sure that spontaneous seroconverters had a limited chance to receive antiviral treatment in the HBeAgpositive phase, while NUC-induced HBeAg seroconverters could access the treatment easily in the HBeAg-positive phase. We thus enrolled all spontaneous seroconverters before 2004 and all NUC-induced seroconverters after 2004. This time frame was chosen because the Taiwanese government has launched a nationwide reimbursement program of applying NUC treatment for chronic hepatitis B patients since 2004 [27, 28] .
A few limitations existed in our study. First, most of the NUC-induced HBeAg seroconverters (92.6%) received lamivudine therapy. This is because lamivudine is the first NUC to be approved for the treatment of chronic hepatitis B worldwide and was extensively used in Taiwan from 2004 to 2008 [27, 28] . It therefore provided adequate patient numbers with a long follow-up period for analysis. However, 2 potent NUCs, entecavir and tenofovir, are now recommended as first-line treatment for chronic hepatitis B. Because of the high genetic barrier for drug-resistance development, it is unclear whether consolidation therapy of 1 year or longer using potent NUCs decreases the risk of HBV reactivation. In other words, whether our findings still hold true in potent NUC-induced HBeAg seroconverters remains unknown and needs to be validated. Second, HBV reactivation, cirrhosis, and HCC are usually regarded as sequential events of chronic hepatitis B infection [2] . The later 2 complications have been recognized as more solid endpoints than HBV reactivation. The current therapeutic standard has meant that patients with HBeAg-negative hepatitis receive therapy more promptly and for longer duration than historical controls, which reduces cirrhosis and HCC development [29, 30] . This influences the accuracy of using these 2 complications as endpoints. Hence, to more accurately compare these 2 study cohorts, we adopted HBV reactivation as our endpoint, which usually occurs before antiviral treatment.
In summary, NUC-induced HBeAg seroconverters do not always achieve sustained serologic or virologic response after stopping therapy. For patients who achieved HBeAg seroconversion before age 30 years, the risk of HBV reactivation is higher in NUC-induced HBeAg seroconverters compared with spontaneous seroconverters. Therefore, close follow-up rather than immediate NUC therapy is advised for young Asian HBeAg-positive noncirrhotic patients with active but compensated disease.
